ReviewClinical microbiology reviews1998
Quantitation of cytomegalovirus: methodologic aspects and clinical applications.
Review in Clinical microbiology reviews, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2009Guideline
- Cytomegalovirus infection in critically ill patients: a systematic review.Critical care (London, England) · 2009Pooled it
- Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.Bone marrow transplantation · 2008Guideline
- Management of CMV infections: recommendations from the infectious diseases working party of the EBMT.Bone marrow transplantation · 2004Guideline
- Cytomegalovirus infection in solid organ transplantation: economic implications.PharmacoEconomics · 2003Pooled it
- Mathematical Modeling of Within-Host, Untreated, Cytomegalovirus Infection Dynamics after Allogeneic Transplantation.Viruses · 2021Trial
- Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.International journal of hematology · 2012Trial
- Relapsing peritoneal dialysis‑associated peritonitis caused by Pseudomonas oryzihabitans with concurrent tunnel infection: a case report and literature review.CEN case reports · 2026Review
- A comprehensive method for quantifying human cytomegalovirus plaque assays.Frontiers in cellular and infection microbiology · 2026Article
- Peptide-Based Plasmon-Enhanced Spectroscopic Immunoassay to Detect Immunity Against Cytomegalovirus.Biosensors · 2025Article
- Article
- Article
- Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients: Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation.Infection & chemotherapy · 2024Review
- Case report: CMV retinitis following local and systemic immunosuppression.Frontiers in ophthalmology · 2024Article
- Long-term CMV monitoring and chronic rejection in renal transplant recipients.Frontiers in cellular and infection microbiology · 2023Article
- Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation.Frontiers in immunology · 2022Review
- Plasma cytomegalovirus DNA load predicts outcomes in liver transplant recipients.Immunity, inflammation and disease · 2021Article
- Breast Milk: A Meal Worth Having.Frontiers in nutrition · 2021Review
- History of hematopoietic cell transplantation: challenges and progress.Haematologica · 2020Review
- Evaluation of current diagnostic methods for COVID-19.APL bioengineering · 2020Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cytomegalovirus (CMV) is an important pathogen in transplant recipients and human immunodeficiency virus (HIV)-infected individuals. Major progress has been made in developing quantitative detection methods for CMV in recent years. Due to their high sensitivity, these assays can detect CMV early, and quantitation may be useful in predicting the patient's risk for disease and in monitoring the effect of antiviral therapy. This review discusses methodological aspects of currently used quantitative assays for CMV (i.e., viral culture techniques, antigen detection assays, DNA detection assays including PCR, branched-DNA assay, and the DNA hybrid capture assay) and addresses the correlation of systemic and site-specific CMV load and CMV disease in different populations of immunosuppressed patients as well as the response to antiviral treatment. To date, direct antigen detection and molecular techniques have largely replaced traditional culture-based techniques for CMV quantitation. In general, a high systemic CMV load is correlated with CMV disease. This correlation is strong in the HIV-infected population and in solid-organ transplant recipients but less clear in allogeneic marrow transplant recipients. Measuring the viral load at specific anatomic sites may be an alternative way to assess disease activity in situations where the systemic viral load correlates poorly with disease activity. A reduction of the systemic CMV load also correlates with a response to antiviral treatment, but more research is needed to evaluate the role of viral load as a surrogate marker for drug resistance. Due to the widespread use of quantitative CMV detection techniques to direct and monitor antiviral treatment, there is a great need for an assessment of the reproducibility of test results and better standardization of the assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.